SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON D.C. 20549


                                   FORM 8-K/A
                                 AMENDMENT NO. 1

                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


         Date of Report (Date of earliest event reported): March 5, 1997


                                 CRYOLIFE, INC.
               (Exact name of registrant as specified in charter)


                        Commission File Number - 0-21104

                Florida                                 59-2417093
    (State or other jurisdiction of           (IRS Employer Identification No.)
            incorporation)




     1655 Roberts Boulevard, N.W.
           Kennesaw, Georgia                                          30144
(Address of principal executive offices)                            (Zip Code)




        Registrant's telephone number including area code (770) 419-3355



  (Former name or former address, if changed since last report) Not Applicable















     EXPLANATORY  NOTE: On March 19, 1997,  CryoLife,  Inc.  (the  "Registrant")
filed with the Securities and Exchange Commission (the "Commission") a Report on
Form 8-K (the "Initial 8-K Report") with respect to the  Registrant's  merger of
Ideas for Medicine,  Inc., a Florida  corporation ("IFM") with and into CryoLife
Acquisition Corporation, a Florida corporation wholly-owned by the Registrant.

     In accordance with Item 7(a)(4) of Form 8-K, the Initial 8-K Report did not
include the historical IFM financial  statements and the condensed  consolidated
pro forma financial information of the Registrant (the "Financial  Information")
and instead contained an undertaking to file the Financial  Information with the
Commission in an amendment to the Initial 8-K Report as soon as practicable, but
not later than 60 days after March 20, 1997.  This  amendment is being filed for
the purpose of satisfying  the  Registrant's  undertaking  to file the Financial
Information,  and this amendment  should be read in conjunction with the Initial
8-K Report.

ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS.

         (a)      Financial Statements.

         The  balance  sheet of IFM as of  December  31,  1996,  and the related
statements  of income and retained  earnings,  and cash flows for the year ended
December 31, 1996,  together  with the related notes and audit report of Ernst &
Young LLP, are included herein.



413659.6


                                       -1-








                         Report of Independent Auditors


Board of Directors and Shareholders
Ideas for Medicine, Inc.

We have audited the accompanying balance sheet of Ideas for Medicine, Inc. as of
December 31, 1996,  and the related  statements of income and retained  earnings
and cash  flows for the year then  ended.  These  financial  statements  are the
responsibility of the Company's management.  Our responsibility is to express an
opinion on these financial statements based on our audit.

We conducted our audit in accordance with generally accepted auditing standards.
Those standards  require that we plan and perform the audit to obtain reasonable
assurance   about  whether  the  financial   statements  are  free  of  material
misstatement.  An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements.  An audit also includes
assessing the  accounting  principles  used and  significant  estimates  made by
management,  as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.

In our opinion,  the financial  statements  referred to above present fairly, in
all material  respects,  the financial  position of Ideas for Medicine,  Inc. at
December 31, 1996,  and the results of its operations and its cash flows for the
year then ended, in conformity with generally accepted accounting principles.

February 5, 1997                                              ERNST & YOUNG LLP


413659.6


                                       -2-





                            IDEAS FOR MEDICINE, INC.
                                  BALANCE SHEET
                                DECEMBER 31, 1996

ASSETS
Current assets:
   Cash                                                         $       180,408
   Accounts receivable, net of allowance for
     doubtful accounts of $10,590                                       741,352
   Inventories                                                          651,882
   Prepaid expenses                                                      47,311
                                                                     -----------
Total current assets                                                  1,620,953

Property and equipment, net                                             200,065
Other assets, net                                                         6,586
                                                                     -----------
                                                                $     1,827,604
LIABILITIES AND SHAREHOLDERS' EQUITY 
Current liabilities:
   Accounts payable                                             $       220,240
   Accrued liabilities                                                   64,020
                                                                     -----------
Total current liabilities                                               284,260

Commitments and contingencies

Shareholders' equity:
   Common stock, $.01 par value; 150,000 shares
           authorized; 105,590 shares issued and
           outstanding                                                    1,056
   Additional paid-in capital                                           642,768
   Retained earnings                                                    899,520
                                                                     -----------
Total shareholders' equity                                            1,543,344
                                                                     -----------
                                                                $     1,827,604
                                                                     ===========
See accompanying notes.
413659.6


                                       -3-





                            IDEAS FOR MEDICINE, INC.

                    STATEMENT OF INCOME AND RETAINED EARNINGS

                          YEAR ENDED DECEMBER 31, 1996


Net sales                                                       $     6,344,114
Cost of sales                                                         3,331,669
                                                               ----------------
Gross profit                                                          3,012,445
Selling, general and administrative expenses                          2,660,051
                                                               ----------------
Operating income                                                        352,394

Other income, net                                                         1,805
                                                               ----------------

Net income                                                              354,199
Retained earnings at beginning of year                                1,095,321
                                                               ----------------
                                                                      1,449,520
Less distributions paid                                                 550,000
                                                               ----------------
Retained earnings at end of year                                $       899,520
                                                               ================

See accompanying notes.



413659.6


                                       -4-





                            IDEAS FOR MEDICINE, INC.

                             STATEMENT OF CASH FLOWS

                          YEAR ENDED DECEMBER 31, 1996

OPERATING ACTIVITIES
Net income                                                   $          354,199
Adjustments to reconcile net income to net cash
     provided by operating activities:
         Depreciation and amortization                                  153,952
         Provision for doubtful accounts                                 11,272
         Loss on disposal of assets                                       5,181
         Changes in operating assets and liabilities:
             Accounts receivable                                         61,023
             Inventories                                                (35,856)
             Other assets                                                16,046
             Accounts payable and accrued liabilities                    93,029
                                                                      ---------
Net cash provided by operating activities                               658,846

INVESTING ACTIVITIES
Purchases of property and equipment                                    (107,579)
Net cash used in investing activities                                  (107,579)

FINANCING ACTIVITIES
Payments of note                                                        (12,398)
Distributions paid                                                     (550,000)
                                                                      ---------
Net cash used in financing activities                                  (562,398)
                                                                      ---------
Net decrease in cash                                                    (11,131)
Cash at beginning of year                                               191,539
                                                                       --------
Cash at end of year                                          $          180,408
                                                                       ========

SUPPLEMENTAL DISCLOSURE OF CASH FLOW
     INFORMATION
Interest paid                                                $              157
                                                                     ==========

See accompanying notes.




413659.6


                                       -5-





                            IDEAS FOR MEDICINE, INC.

                          NOTES TO FINANCIAL STATEMENTS

                          YEAR ENDED DECEMBER 31, 1996

1.   NATURE OF BUSINESS

Ideas for Medicine,  Inc. (the "Company) is a closely-held  Florida corporation.
The Company designs and manufactures a variety of surgical devices.  The devices
are marketed  primarily to hospitals  in the United  States and  throughout  the
world through stocking and non-stocking  distributors.  The Company's  corporate
offices and manufacturing facilities are located in Clearwater, Florida.

2.   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

REVENUE RECOGNITION

Sales are recorded when the related goods are shipped.

INVENTORIES

Inventories are stated at the lower of average cost or market.

PROPERTY AND EQUIPMENT

Property and equipment is recorded at cost.  Depreciation is computed  primarily
using accelerated methods over the following useful lives:

                  Manufacturing Equipment                           5-7 years
                  Office furniture and equipment                    5-7 years
                  Leasehold improvements                        Life of lease

PATENTS

Patent costs are expensed in the period in which they are incurred.

INCOME TAXES

The Company operates as an "S" Corporation  under the Internal Revenue Code and,
consequently,  is not subject to federal income tax. The Company's  shareholders
include their  proportionate  shares of the Company's income in their individual
income tax returns.



413659.6


                                       -6-





                            IDEAS FOR MEDICINE, INC.

                    NOTES TO FINANCIAL STATEMENTS (CONTINUED)


2.   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

USE OF ESTIMATES

The  preparation  of the  financial  statements  in  conformity  with  generally
accepted  accounting  principles  requires  management  to  make  estimates  and
assumptions  that affect the amounts  reported in the financial  statements  and
accompanying notes. Actual results could differ from those estimates.

3.   INVENTORIES

Inventories consist of the following at December 31, 1996:

Finished Goods                                              $         317,757
Work-in-process                                                        53,663
Raw Materials                                                         280,462
                                                                      -------
                                                            $         651,882


4.   PROPERTY AND EQUIPMENT

Property and equipment consist of the following at December 31, 1996:

Manufacturing equipment                                     $         450,390
Office furniture and equipment                                        215,334
Leasehold improvements                                                101,750
                                                                      -------
                                                                      767,474

Less accumulated depreciation
     and amortization                                                 567,409
                                                                      -------
                                                            $         200,065
                                                                      =======



5.   RESEARCH AND DEVELOPMENT EXPENSES

Research and development expenses,  aggregating $260,000 in 1996 are expensed as
incurred.




413659.6


                                       -7-





                            IDEAS FOR MEDICINE, INC.

                    NOTES TO FINANCIAL STATEMENTS (CONTINUED)


6.   CREDIT ARRANGEMENTS

Under a revolving  line of credit  arrangement  dated  September 27, 1996 with a
bank,  the Company may borrow up to $250,000 with  borrowings due and payable on
demand. No amounts were borrowed under such line during 1996.

7.   COMMITMENTS AND CONTINGENCIES

During 1996 the Company leased its facilities under a  non-cancelable  operating
lease which expired  December 31, 1996. Rent expense for 1996 totaled  $172,000.
Effective January 1, 1997, the Company leases its manufacturing  facilities on a
month-to-month  basis (see Note 8) and its  office  facility  is leased  under a
non-cancelable  operating  lease  expiring on December  31,  1997.  Minimum rent
payments under this one-year lease total $20,000.

8.   RELATED PARTY TRANSACTIONS

The Company leases its manufacturing facilities from shareholders of the Company
under month-to-month leases for $7,000 per month.

9.   CONCENTRATION OF CREDIT RISK

The  Company  maintains  the  majority  of its cash  balances  at one  financial
institution.  These  balances  are  insured  by the  Federal  Deposit  Insurance
Corporation  up to $100,000.  The uninsured  balance on deposit at the financial
institution totaled $220,000 at December 31, 1996.

10.  FAIR VALUE OF FINANCIAL INSTRUMENTS

The  carrying  amounts  reported  in  the  balance  sheet  for  cash,   accounts
receivable, and accounts payable approximate their fair values.

11.  LEGAL COSTS

During 1996 the Company incurred legal expenses aggregating $117,000 relating to
the settlement of three separate lawsuits.





413659.6


                                       -8-





                            IDEAS FOR MEDICINE, INC.

                    NOTES TO FINANCIAL STATEMENTS (CONTINUED)



12.  GEOGRAPHIC AREA

The Company  produces  surgical  devices for  hospitals in the United States and
throughout  the  World.  All  sales  are to  unaffiliated  customers.  Sales  to
international distributors aggregated $1,304,000 in 1996.

13.  PROPOSED MERGER

The Company is involved in  negotiations  with a third-party  corporation  for a
proposed  merger  of the  Company  with and into a  wholly-owned  subsidiary  of
CryoLife,  Inc.  The  accompanying  financial  statements  do  not  include  any
adjustments  which may be  required  upon the  successful  completion  of such a
merger.

14.  EVENT SUBSEQUENT TO DATE OF AUDITORS' REPORT

On  March  5,  1997  CryoLife,  Inc.  acquired  the  stock  of the  Company  for
consideration of approximately $4.5 million in cash and approximately $5 million
in convertible  debentures plus related expenses.  The acquisition was accounted
for as a purchase.






413659.6


                                       -9-





         (b)  Unaudited Pro Forma Condensed Consolidated Financial Information.

         Set  forth  below  are the  following  unaudited  pro  forma  condensed
         consolidated financial statements:

              1.   Introduction  to Condensed  Consolidated  Pro Forma Financial
                   Statements.

              2.   ProFormaCondensed  Consolidated  Statement  of Income for the
                   Year Ended December 31, 1996.

              3.   ProForma Condensed  Consolidated Balance Sheet as of December
                   31, 1996.



413659.6


                                      -10-





                   UNAUDITED PRO FORMA CONDENSED CONSOLIDATED
                              FINANCIAL INFORMATION

     INTRODUCTORY NOTE: The following unaudited pro forma condensed consolidated
balance sheet and statement of income reflect the financial position at December
31,  1996 and  results of  operations  for the year ended  December  31, 1996 of
CryoLife,  Inc. (the  "Registrant")  as if the acquisition of Ideas for Medicine
(IFM) on March 5, 1997 had  occurred on  December  31, 1996 and January 1, 1996,
respectively.

     The unaudited pro forma condensed  consolidated balance sheet and statement
of income do not purport to represent  the  Registrant's  financial  position or
results of operations  had the  transactions  actually  occurred on December 31,
1996  or  January  1,  1996,  respectively,   or  to  project  the  Registrant's
consolidated results of operations for any future periods.

     The pro forma  adjustments  are based  upon  available  information.  These
adjustments are directly  attributable to the transaction referred to above, and
are expected to have a continuing impact on the Registrant's  business,  results
of  operations,  and  financial  position.  The  following  unaudited  pro forma
condensed  consolidated  financial statements should be read in conjunction with
the historical financial statements of the Registrant, which are included in its
Form 10-K for the year ended  December 31, 1996,  and Ideas for Medicine,  Inc.,
which are included elsewhere herein.


413659.6


                                      -11-



CRYOLIFE, INC. PROFORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME YEAR ENDED DECEMBER 31, 1996 (UNAUDITED) IDEAS FOR PRO FORMA CRYOLIFE, INC. MEDICINE CONSOLIDATED YEAR ENDED YEAR ENDED PRO FORMA YEAR ENDED 12/31/96 12/31/96 ADJUSTMENTS 12/31/96 ------------------ ---------------- --------------- ------------------ REVENUES: Cryopreservation and product $ 36,678,000 $ 6,344,000 $ 43,022,000 Grants, licenses and other 361,000 361,000 Interest income 189,000 2,000 191,000 ----------- ---------- ----------- Total revenues 37,228,000 6,346,000 43,574,000 COST AND EXPENSES: Preservation costs and cost of products sold 12,593,000 3,332,000 15,925,000 General and administrative 15,673,000 2,510,000 $ 200,000 (A) 18,531,000 10,000 (B) 488,000 (C) (350,000)(D) Research and development 2,807,000 150,000 2,957,000 Interest expense 72,000 733,000 (E) 805,000 ------------ -------------- -------- --------- Total costs and expenses 31,145,000 5,992,000 1,081,000 38,218,000 Income before income taxes 6,083,000 354,000 (1,081,000) 5,356,000 Income tax expense (benefit) 2,156,000 (240,000) (F) 1,916,000 Net income $ 3,927,000 $ 354,000 $ (841,000) $ 3,440,000 =========== ============ ========== ============ Earnings per share of common stock $ 0.40 $ 0.35 ============= ============== Weighted average common and common equivalent shares outstanding 9,906,000 9,906,000 =========== ============
(A) Represents consulting agreement with former principal owner of Ideas for Medicine. (B) Represents automobile allowance with former principal owner of Ideas for Medicine. (C) Represents amortization associated with intangible assets recorded in connection with the acquisition. (D) Adjustments for the salary of personnel who are no longer with the Registrant. (E) Adjustments of interest expense for borrowings and indebtedness related to the acquisition. (F) Income tax benefit related to additional expenses and IFM subchapter S pretax income. 413659.6 -12-
CRYOLIFE, INC. PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET DECEMBER 31, 1996 Ideas for CryoLife, Inc. Medicine Consolidated Pro December 31, December 31, Pro Forma Forma December 1996 1996 Adjustments 31, 1996 ---------------- ----------------- -------------- ----------------- ASSETS: Cash $ 1,370,000 $ 181,000 $ 1,551,000 Marketable Securities 43,000 43,000 Receivables, net 8,197,000 741,000 $ (23,000)(A) 8,915,000 Deferred preservation costs 7,178,000 7,178,000 Inventories 260,000 652,000 84,000 (B) 996,000 Prepaid expenses 846,000 47,000 893,000 Deferred income taxes 287,000 287,000 ----------- -------------- ----------- ----------- Total current assets 18,181,000 1,621,000 61,000 19,863,000 Property and equipment 11,567,000 200,000 (100,000)(C) 11,667,000 Goodwill 1,846,000 6,873,000 (D) 8,719,000 Other intangibles 3,379,000 7,000 1,697,000 (D) 5,083,000 ----------- ----------- --------- --------- Total assets $ 34,973,000 $ 1,828,000 $ 8,531,000 $ 45,332,000 ========== ========== ========= ========== LIABILITIES Accounts payable $ 3,696,000 $ 220,000 $ 3,916,000 Accrued expenses 934,000 64,000 $ 575,000 (E) 1,573,000 Accrued procurement fees 1,210,000 1,210,000 Current maturities of debt 527,000 527,000 Accrued compensation 878,000 878,000 ----------- ------------- ------------- ----------- Total current liabilities 7,245,000 284,000 575,000 8,104,000 Bank line of credit 1,250,000 4,500,000 (F) 5,750,000 Long-term debt 1,549,000 5,000,000 (F) 6,549,000 Shareholders' equity Common Stock 101,000 1,000 (1,000)(G) 101,000 APIC 17,128,000 643,000 (643,000)(G) 17,128,000 Retained earnings 7,902,000 900,000 (900,000)(G) 7,902,000 Treasury stock (1,000) (1,000) Shareholder notes receivable (180,000) (180,000) Unrealized loss (21,000) (21,000) ---------- --------- --------- ------------- Total liabilities and shareholders' equity $ 34,973,000 $ 1,828,000 $ 8,531,000 $ 45,332,000 ========== ========= ========= ==========
413659.6 -13- CRYOLIFE, INC. PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET DECEMBER 31, 1996 (A) To adjust accounts receivable to net realizable value. (B) To write up finished goods inventory to net realizable value. (C) To adjust property and equipment to net realizable value as a result of the Registrant's intentions to replace certain equipment in connection with construction of IFM's new office/manufacturing facilities. (D) To record goodwill and other intangible assets resulting from the acquisition of IFM. The expected useful lives of such assets range from 5 to 20 years. (E) To accrue expenses associated with the acquisition. (F) To record borrowings on the line of credit and the issuance of the convertible subordinated debenture in connection with the acquisition of IFM. The former stockholders of IFM received an aggregate consideration of $9.5 million, consisting of $4.5 million in cash and a convertible subordinated debenture in the principal amount of $5 million. (G) To eliminate the equity of IFM. 413659.6 -14- (c) Exhibits. Exhibit Number Description - ------ ----------- 2.1* Agreement and Plan of Merger dated as of March 5, 1997 among the Registrant, Ideas For Medicine, Inc. ("IFM") and Stockholders of IFM. 23.1 Consent of Ernst & Young LLP - -------------------------- * PREVIOUSLY FILED. 413659.6 -15- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CRYOLIFE, INC. Date: May 15, 1997 By: /s/ Edwin B. Cordell, Jr. ------------------------------------ Edwin B. Cordell, Jr., Vice President and Chief Financial Officer 413659.6 EXHIBIT INDEX Exhibit Number Description ------ ----------- 2.1* Agreement and Plan of Merger dated as of March 5, 1997 among the Registrant, Ideas For Medicine, Inc. ("IFM") and Stockholders of IFM. 23.1 Consent of Ernst & Young LLP - ------------------ * PREVIOUSLY FILED. 413659.6




                                  EXHIBIT 23.1



413659.6


                                     





                         CONSENT OF INDEPENDENT AUDITORS





We consent to the  incorporation  by reference  in  Registration  Statement  No.
333-16581  on Form  S-3 and  Registration  Statement  Nos.  33-83996,  33-84048,
333-03513 and 333-06141 on Forms S-8 pertaining to CryoLife, Inc., of our report
dated  February 5, 1997,  with respect to the financial  statements of Ideas for
Medicine, Inc., included in CryoLife,  Inc.'s Form 8-K/A (Amendment No. 1) dated
March 5, 1997.


                                            Ernst & Young LLP


Atlanta, Georgia
May 13, 1997



413659.6